评估接受自体造血细胞移植 (auto-HCT) 的初次治疗失败 (PTF) 经典霍奇金淋巴瘤 (cHL、PTF-cHL) 风险评分的数据有限。 ECLIPSE 是一项多中心回顾性队列研究，纳入 2005 年 1 月 1 日或之后在 15 个美国医疗中心诊断出的 PTF-cHL 患者（15 岁或以上）。 PTF 被定义为以下失败模式之一： [1] 在一线化疗期间或完成后 6 周内通过影像学检查发现疾病进展（原发性进展 [PP]）； [2] 完成一线治疗后影像学显示部分缓解（PR）或疾病稳定（SD）（PR/SD）； [3] 在事先记录完全缓解（CR、早期复发 [ER]）后，一线治疗完成后 12 个月内通过影像学检查（并通过活检证实）疾病进展。共有 478 名患者参与分析。其中，217 例（45%）为 PP，86 例（18%）为 PR/SD，175 例（37%）为 ER。自体 HCT 后 6 个月和 1 年累计非复发死亡率分别为 0.9% 和 1.1%。自动 HCT 后的中位 PFS 和 OS 分别为 4.33 年和 10.09 年。虽然自动 HCT 时未达到 CR 的患者与较差的 PFS 和 OS 相关，但高龄和 2011 年之前诊断的患者与较差的 OS 相关。这项研究展示了自动 HCT 的安全性和长期疗效，即使对于传统上被认为是化疗难治的高危疾病患者也是如此，并将作为正在进行的移植与不移植试验的基准。版权所有 © 2024 美国学会血液学。

There are limited data assessing the risk scores for primary treatment failure (PTF) classical Hodgkin lymphoma (cHL, PTF-cHL) undergoing autologous hematopoietic cell transplantation (auto-HCT). ECLIPSE is a multicenter retrospective cohort of patients with PTF- cHL (15 years or older) diagnosed on or after Jan 1, 2005, at 15 US medical centers. PTF was defined as one of the following patterns of failure: [1] progressive disease by imaging during or within 6 weeks of completion of frontline chemotherapy (primary progression [PP]); [2] partial response (PR) or stable disease (SD) by imaging after completion of frontline treatment (PR/SD); [3] progression of disease by imaging (and confirmed by biopsy) within 12 months of frontline therapy completion after prior documentation of complete response (CR, early relapse [ER]). A total of 478 patients were included in the analysis. Among these, 217 (45%) were PP, 86 (18%) were PR/SD, and 175 (37%) were ER. The 6-month and 1-year cumulative incidence of non-relapse mortality following auto-HCT was 0.9% and 1.1%, respectively. The median PFS and OS following auto-HCT were 4.33 years and 10.09 years, respectively. While those not in CR at the time of auto-HCT was associated with inferior PFS and OS, advanced age and those diagnosed before 2011 were associated with inferior OS. This study showcases the safety and long-term efficacy of auto-HCT, even in patients with high risk disease who are traditionally considered chemo-refractory and will serve as a benchmark for the ongoing transplant vs no transplant trials.Copyright © 2024 American Society of Hematology.